News

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.

In this analysis, investigators looked at the importance of skin clearance and daily time trade off (dTTO) among adult patients living with chronic hand eczema (CHE).

Check out the top 5 psychiatry headlines in August 2025, including the fast-track designation of NRX-100 for suicidal ideation.

Check out expert perspectives on unmet needs and advances in gastroparesis and new research on C. diff, IBS, and more in this August 2025 recap.

Merck’s investigational oral PCSK9 inhibitor reduced LDL-C, non-HDL-C, ApoB, and LP(a) significantly compared to placebo after 24 weeks.

Upstream Bio’s VIBRANT trial finds verekitug, a monoclonal antibody binding to the TSLP receptor, reduces nasal polyps in patients with CRSwNP.

Check out expert perspectives on semaglutide’s FDA approval for MASH and new research on PBC, infectious disease screening, and more in this August 2025 recap.

Ionis Therapeutics, Inc. also announced plans to submit an sNDA for olezarsen based on these trial results by the end of 2025.

This analysis looked at a Hispanic patient cohort, systematically linking specific trichoscopic patterns with clinical outcomes related to scalp psoriasis.

This Month in Review summary includes a list of some of the most notable stories in the dermatology field from August 2025.

Vancomycin was linked to a higher risk of acute kidney injury than alternative antibiotics, underscoring the need for appropriate prevention strategies.

Alnylam Pharmaceuticals debuts phase 2 KARDIA-3 data at ESC 2025 and advances zilebesiran into a phase 3 outcomes trial.

Olezarsen shows promise in significantly lowering triglyceride levels in patients with hypertriglyceridemia.

The investigative aldosterone synthase inhibitor reduced seated systolic blood pressure in patients with uncontrolled or resistant hypertension compared to placebo.

Aficamten shows significant benefits over metoprolol in treating symptomatic obstructive HCM, potentially changing first-line therapy approaches.

Aficamten displayed superior improvements in peak oxygen uptake and hemodynamics compared to the most commonly used beta-blocker for symptomatically obstructive HCM.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Javed Butler, MD, to discuss the results of this major trial.

Stay updated with the latest healthcare breakthroughs, including FDA news, vaccine guidelines, and orforglipron data, in this week's essential news roundup.

Discover how the LEADDerm meeting transforms dermatology through leadership, collaboration, and personal development.

FDA approval of weekly subcutaneous lecanemab-irmb offers at-home maintenance therapy for early Alzheimer’s after initial intravenous treatment.

This analysis highlights the global prevalence of HS and some of the most significant global variations in HS prevalence.

The basophil activation test shows the greatest accuracy in predicting allergic reactions to baked and fresh cow’s milk, reducing the need for oral food challenges in children.

Multidisciplinary management and patient-centered care are critical for optimizing outcomes in complex or severe psoriasis cases.

The 9-week intervention targeting positive psychological wellbeing in IBS was feasible, well-accepted, and linked to improvements in IBS-related outcomes.

Combining salivary bacteria, serum markers, and past attack history improves risk prediction for severe asthma attacks in children.

This analysis suggests that this AI model effectively classifies skin irritation in patch tests, allowing for quicker and more accurate dermatologic assessments.